Skip to content
    UFPT
    Earnings call· Jun 2026(Q2 FY26)

    UFP TECHNOLOGIES Q2 FY26 earnings call UFPT

    Aug 4, 2026 Source

    Executive summary

    UFP Technologies Q2 FY26 — Strong MedTech Growth and Record Adjusted EPS

    UFP Technologies delivered a strong second quarter, driven by broad-based growth across its diverse MedTech portfolio, leading to record adjusted EPS. The company continues to invest in capacity expansion and organizational leadership, while navigating raw material inflation and delays in realizing full benefits from its Dominican Republic investments. Management remains focused on disciplined execution and strategic acquisitions for long-term value creation.

    Highlights

    5

    • Sales increased 15.1% to $174 million.

    • Gross margins increased to 29.3% from 28.8% last year.

    • Adjusted EPS grew 16.8% to a company record of $2.92.

    • Organic sales growth was strong at 12.4%.

    • Growth remained broad-based, with top 5 customers growing 14.7% and balance of MedTech growing 19.7%.

    Concerns

    3

    • Full realization of Dominican Republic investment benefits taking longer than anticipated.

    • Continued margin pressure at AJR due to customer qualification delays for program transfers to DR.

    • Inflationary price increases on petroleum-based raw materials due to Iran conflict.

    Guidance & targets

    2
    CategoryTargetConfidence
    Organic sales growth
    6% to 9%
    medium materiality
    Medium
    Robotic-assisted surgical programs contribution
    8-figure contribution and growing
    medium materiality
    High

    Segment performance

    1
    SegmentRevenueYoYQoQMargin
    MedTech Business
    Growth remained broad-based throughout the portfolio, driven by a diverse set of customer programs and continued execution across various submarkets including surfaces and support, cardiovascular, infection control, and orthopedics.
    Top 5 customers growth: 14.7%Balance of MedTech business growth: 19.7%
    		$174M15.1%——

    Operational metrics

    10
    Organic sales growth
    12.4%
    Q2 FY26

    Fueled by strength across our platform, as launch programs accelerate and capacity builds at AJR.

    Gross margin
    29.3%up from 28.8% last year
    Q2 FY26

    Improvement despite continued margin pressure at AJR due to customer qualification delays for DR transfers.

    SG&A expenses
    $22.8Mincreased by $4.1M
    Q2 FY26

    Largely due to investments in back-office and senior management team, including CEO transition costs. Current level is expected to be the new normal, with some temporary relief mid-2027.

    Adjusted operating margin
    17.6%
    Q2 FY26
    Adjusted EPS
    $2.92up 16.8%
    Q2 FY26

    Company record.

    Capital expenditures
    $1.2M
    Q2 FY26
    Leverage ratio
    under 1x
    Q2 FY26

    Ended the quarter with a leverage ratio of under 1x.

    M&A pipeline opportunities
    5 to 10
    Current

    Robust pipeline of opportunities to expand capabilities and strengthen position in MedTech markets.

    Net new programs
    3
    FY26

    These programs are being transferred into us from outside and contributed to the quarter as expected.

    Dominican Republic program transfers
    2 of 3
    Current

    Two of the three original programs planned for transfer to the DR have transferred; the third is delayed due to customer qualification.

    Industry KPIs

    4
    MetricValueDetails
    New product launch ramp8-figure contributionUSD
    FCF conversion leverage guidanceunder 1x
    Segment franchise organic growth12.4%%
    Sales force commercial capacity build—

    Product announcements

    2
    ProductTypeDetails
    New programs (general)launch
    Robotic-assisted surgical programslaunch

    Deals & partnerships

    1
    Various (unnamed)Evaluating businesses that can expand capabilities and strengthen position in attractive MedTech markets.5 to 10 opportunities ranging from $5M to $30M of EBITDA

    Acquisition strategy remains unchanged, with a robust pipeline of opportunities. Committed to deploying capital in ways that create long-term shareholder value.

    Risks & headwinds

    3
    Full realization of benefits from Dominican Republic investmentsOngoing

    Taking longer than originally anticipated

    Mitigation: Remain confident in long-term value; continued efforts to support customer-driven growth initiatives.

    Margin pressure at AJROngoing

    Continued

    Mitigation: Programs scheduled to be transferred to the DR are contingent on customer qualification.

    Inflationary price increases on petroleum-based raw materialsOngoing, volatile

    Due to impact on oil prices from the conflict in Iran

    Mitigation: Expectation to pass through these increases to the market.

    What to watch in Q3 FY26

    4

    Organic sales growth rate

    Rest of FY26
    Current12.4%
    TargetWithin 6% to 9% target range

    Why it matters

    To assess if the company can maintain its long-term growth target after a strong Q2, considering the easier comparable base from Q2 FY25.

    The second quarter organic growth was impressive, but you have to remember that second quarter of last year was kind of the low point for the labor inefficiencies that we had. So I think as we go out through the rest of the year, the comp from a year ago will begin to improve. So I think we will be in our target range for organic growth, but I don't think you'll see the same double digits that you saw in Q2.

    Q&A highlights

    7

    Asked for more detail on the strength, specifically mentioning surfaces and support, cardiovascular, infection control, and orthopedics.

    Mitch Rock confirmed growth across core markets like cardiovascular, infection prevention, patient handling, and orthopedics, noting that robotic surgical market was flat to down as expected. He emphasized broad-based growth from existing customer relationships and product families rather than new launches.

    “We continue to see growth across several of the core markets, including cardiovascular, infection prevention, patient handling, orthopedics.”

    asked by Brett Fishbin · answered by Mitchell Rock

    1 min read6 chapters

    Detailed Narrative

    01

    Leadership Transition and Strategic Continuity

    Mitch Rock's first earnings call as CEO emphasized continuity of strategy, focusing on customer support, team investment, disciplined acquisitions, and long-term shareholder value. The company continues to strengthen its organization with recent additions in business development, operations, and legal to support future growth and onboard additional companies into its decentralized operating model.

    02

    Broad-Based MedTech Growth

    The company reported strong Q2 FY26 sales growth of 15.1% to $174 million, with organic sales growth at 12.4%. This growth was broad-based, with top 5 customers growing 14.7% and the balance of the MedTech business growing 19.7%, indicating diversification across customer programs, product categories, and end markets like cardiovascular, infection control, and orthopedics.

    03

    Dominican Republic Investment and Operational Benefits

    Investments in the Dominican Republic aim to support customer-driven growth, expand capacity, and enhance cost structure. While generating early operational benefits, the full realization of these benefits is taking longer than anticipated due to customer qualification requirements for program transfers, particularly for programs scheduled to move from AJR.

    04

    Acquisition Strategy and Pipeline

    UFP Technologies maintains a disciplined acquisition strategy, with a robust pipeline of 5 to 10 opportunities ranging from $5 million to $30 million in EBITDA. The focus remains on evaluating businesses that expand capabilities and strengthen the company's position in attractive MedTech markets, with a commitment to disciplined valuation.

    05

    Raw Material Inflation

    The company faces inflationary price increases on petroleum-based raw materials due to the conflict in Iran, leading to volatile oil prices. Management expects to pass these increases through to the market.

    06

    New Program Ramps

    Three net new programs are being transferred to UFP Technologies from outside, contributing to the quarter's performance as expected. Two robotic-assisted surgical programs have launched and are ramping, with an expected 8-figure contribution and growth moving into FY27.

    AI-generated summary of the company’s earnings call. Not investment advice.